China TCM (570.HK) Update - Despite Doubts, This Privatization Seems “Mandatory”
Xinyao has highlighted this Insight as a Top Pick
555 Views06 May 2024 08:55
Some investors have concerns that the privatization may fail, but China TCM's privatization seems "mandatory", which will lead to spin-off/integrations ahead. We analyzed the big picture/logic behind
What is covered in the Full Insight:
- Investor concerns and Morgan Stanley's target price
- Background and the logic of privatization
- CNPGC's past actions and newly acquired companies
- Chongqing Taiji Industry (Group) A's business structure
- Horizontal competition issues and potential resolution
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- HEC CJ Pharma (1558.HK)'s Merger Deal with Sunshine Lake Pharma - Almost No Investment Value16 May 2024
- China National Medicines (600511.CH) - After Restructuring, Performance Growth Is Guaranteed14 May 2024
- China Healthcare Weekly (May12)-Policy Catalyst in Medical Device, GLP-1 Overvaluation, Pientzehuang12 May 2024
- Tiantan (600161CH) To Acquire Weiguang (002880CH)- New King Rises in China's Blood Products Industry24 Apr 2024
- China TCM (570.HK) - Latest Updates on Privatization and the Potential Merger with Taiji Group10 Apr 2024
- Will China TCM (570.HK) Be Incorporated into Taiji Group (600129.CH)? –If Yes, Valuation Will Double04 Mar 2024
x